Rosales, M.; Pérez, G.V.; Ramón, A.C.; Cruz, Y.; Rodríguez-Ulloa, A.; Besada, V.; Ramos, Y.; Vázquez-Blomquist, D.; Caballero, E.; Aguilar, D.;
et al. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines 2021, 9, 766.
https://doi.org/10.3390/biomedicines9070766
AMA Style
Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D,
et al. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines. 2021; 9(7):766.
https://doi.org/10.3390/biomedicines9070766
Chicago/Turabian Style
Rosales, Mauro, George V. Pérez, Ailyn C. Ramón, Yiliam Cruz, Arielis Rodríguez-Ulloa, Vladimir Besada, Yassel Ramos, Dania Vázquez-Blomquist, Evelin Caballero, Daylen Aguilar,
and et al. 2021. "Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300" Biomedicines 9, no. 7: 766.
https://doi.org/10.3390/biomedicines9070766
APA Style
Rosales, M., Pérez, G. V., Ramón, A. C., Cruz, Y., Rodríguez-Ulloa, A., Besada, V., Ramos, Y., Vázquez-Blomquist, D., Caballero, E., Aguilar, D., González, L. J., Zettl, K., Wiśniewski, J. R., Yang, K., Perera, Y., & Perea, S. E.
(2021). Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines, 9(7), 766.
https://doi.org/10.3390/biomedicines9070766
